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Hypertension is a risk factor for myocardial ischemia via the promotion of endothelial 
dysfunction and atherosclerosis (Ogita et al., 2004). Hypertension not only a predisposes the 
heart to ischemic events, but as shown by clinical and experimental studies, exacerbates the 
heart’s susceptibility to ischemia-reperfusion injury (Golden et al., 1994; Besík et al., 2007; 
Snoeckx et al., 1986) due to impairments in regulation of calcium handling, ion homeostasis, 
and energy metabolism (Galiñanes et al., 2004). Nutraceuticals have demonstrated beneficial 
and protective effects on both hypertension and ischemia reperfusion injury.  Resveratrol, a 
naturally occurring polyphenol which is present in grapes and wine, acts as a cardioprotective 
agent and can be used to protect the heart against ischemia reperfusion injury.    
Here we investigate the effectiveness of chronic dietary resveratrol intake in 
normotensive and hypertensive rats on protection against ischemia-reperfusion injury, assessed 
in an isolated perfused Langendorff heart model. Rats ingested either a High dose of 
2.7mg/day-which mimicked the resveratrol content in daily supplemental intake levels, a Low 
dose of 0.027mg/day- which mimicked the resveratrol content in moderate red wine intake, or 
no resveratrol in the drinking water for 28 days, at which point hearts were excised and 
mounted on a Langendorff apparatus.  Once stable conditions were established all hearts were 
subjected to 30 minutes of no flow ischemia followed by 2 hours of reperfusion.   
Interestingly, SHR animals did not exhibit reduced recovery, or increased infarct size as 
compared to WKY.  Infarct size as measured by triphenyltetrazolium chloride staining after 2 
hours of reperfusion was significantly reduced in High and Low groups (combined WKY and 
SHR) as compared to Controls (19.9±0.9 and 19.4±0.8 vs 27.7±0.7 % of baseline, p<0.0001).  
Left ventricular developed pressure was significantly improved 2 hours post ischemia in both 
High and Low groups (combined SHR and WKY) compared to Controls (83.1±4.1 and 
78.6±3.4 vs.67.9±3.2% of baseline, p<0.01).  A higher rate of maximal pressure development 
was maintained in High and Low groups (combined SHR and WKY) compared to Controls 
(90.5±4.7 and 95.6±5.0 vs.73.5±4.8% of baseline, p<.05).  Resveratrol treatment at a High and 
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Low dose reduced contracture of the myocardium as compared to Control (7.2±3.0 and 6.9±2.9 
vs. 20.1±2.9 mmHg- LVEDP, p<0.01).    
In conclusion resveratrol treatment at both a High and Low dose protects against a 
decline in cardiac function, and reduces infarct size post ischemia reperfusion.  Additionally, 
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  INTRODUCTION 
 
The most recent Canadian statistics indicate that cardiovascular disease accounts for 
approximately 30% of all deaths in Canada, 54% of which are caused by
 
ischemic heart disease 
(CANISM, 2010).  Hypertension not only predisposes the heart to ischemic events, but as shown 
by clinical and experimental studies, exacerbates the heart’s susceptibility to myocardial 
ischemia-reperfusion injury (Golden et al., 1994; Besík et al., 2007; Snoeckx et al., 1986).  Standard 
treatment of myocardial ischemia attempts to restore blood flow.  A paradoxical effect occurs 
upon reperfusion in that it allows for treatment of ischemia, but causes further damage and 
dysfunction to the myocardium.  Studies have shown that treating an individual with a 
pharmacologic agent before ischemia occurs can provide protection against the ischemic insult.  
Resveratrol, a phenolic component of red wine, protects against myocardial ischemia 
reperfusion injury (IRI) when used as a nutraceutical in healthy and diseased models.  As 
recently demonstrated in an isolated perfused heart model, acute treatment with red wine 
extract can elicit cardioprotective effects on spontaneously hypertensive rat (SHR) hearts 
(Fantinelli et al., 2007), though these effects cannot be solely attributed to resveratrol.  
Experimentally, resveratrol prevents the development of pathological cardiac hypertrophy and 
contractile dysfunction in SHR (Thandapilly et al., 2010), though at present there is a lack of 
evidence regarding the cardioprotective effects of chronic resveratrol treatment in SHR 
undergoing ischemia reperfusion (IR).  Additionally, numerous studies have proven the 
cardioprotective effects of direct resveratrol administration to an isolated heart, undergoing 
ischemia reperfusion, via the perfusate in wild type animals (Mokni et al., 2007; Ray et al., 1999; 
Lin et al., 2008; Dernek et al., 2004; Hung et al., 2004).  Acute application to a perfused heart does 
2 
 
not take chronic dietary intake and digestion into consideration, and these methods of treatment 
may result in different mechanistic approaches to cardioprotection.  Here we attempt to 
investigate the effectiveness of chronic dietary and supplemental levels of resveratrol intake in 
normotensive and hypertensive rats on protection against ischemia-reperfusion injury, assessed 
in an isolated perfused Langendorff heart model.  Using functional and biochemical data, the 
effects of resveratrol on cardiac function and viability post ischemia reperfusion will be 
studied.   
The Spontaneously Hypertensive Rat as a Model of Hypertension 
Hypertension, a disorder which affects 20% of Canadian adults, is a modifiable risk 
factor for cardiovascular disease (Wilkins et al., 2010), and can negatively affect the structure 
and function of vital organs including the heart and kidney (Yusuf et al., 2004).  It is defined 
by an elevated systolic blood pressure of 140mmHg and higher, and a diastolic pressure of 
90mmHg and higher (Quinn et al., 2010).  Hypertension is a risk factor for myocardial 
ischemia (Yusuf et al., 2004; Klabunde, 2005) via the promotion of endothelial dysfunction 
and atherosclerosis (Ogita et al., 2004).  Clinical and experimental studies on hypertensive 
individuals also show increased susceptibility to myocardial IRI (Golden et al., 1994; Besík et 
al., 2007; Snoeckx et al., 1986), and reasons for this will be discussed below.  
The spontaneously hypertensive rat will be used as a model of inherited spontaneous 
hypertension in this study, with the Wistar Kyoto rat (WKY) as a normotensive control.  
Essential hypertension accounts for 95% of cases that are diagnosed in patients (Quinn et al., 
2010).  The SHR model is an experimental model that closely mimics the course of untreated 
essential hypertension.  The relative changes in hemodynamic characteristics such as peripheral 
resistance, cardiac output, and heart rate are comparable in their course of action throughout 
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the development of hypertension (Yamori et al., 1973).  Common to both is the development of 
responsive secondary cardiovascular diseases, including left ventricular (LV) hypertrophy 
(Yamori et al., 1973).  LV hypertrophy is an important contributor to cardiovascular morbidity 
and mortality (Ho et al., 1993), as it can lead to the development of heart failure, and can cause 
altered responses of the myocardium to IRI (Ferdinandy et al., 2007).    
Myocardial Ischemia-Reperfusion Injury  
Partial or complete occlusion in one or more areas of the coronary tree renders an 
ischemic myocardial environment.  In a clinical setting of spontaneous myocardial ischemia 
(MI), the occlusion is typically a result of atherosclerotic plaque (Ogita et al., 2004).  An 
infarction occurs when prolonged ischemia and/or reperfusion results in irreversible cell death 
(Cokkinos et al., 2006).  Infarcted tissue is unable to contribute to the generation of contractile 
activity, leaving non infracted areas to compensate.  Over time the increased demand on the 
non infracted tissue may lead to detrimental functional changes and heart failure (Bolli et al., 
1999); therefore it is of utmost importance to prevent or limit the amount of infracted tissue.  
Initial treatment of myocardial ischemia (MI) requires removal of the blockage in order 
to salvage remaining viable tissue, resulting in reintroduction of oxygenated blood to the 
previously ischemic myocardium.  Reperfusion can be obtained clinically via angioplasty, 
thrombolytic therapy, and bypass surgery (Cokkinos et al., 2006).  In combination with 
irreversible cell death, ischemia causes reversible damage that can be eliminated by reperfusion 
(Bolli et al., 1999).  Paradoxically, reperfusion is fundamental for the treatment of ischemia but 
also generates an environment which can cause further damage or death to the myocardium 
with mechanisms distinct from those of ischemic injury (Yellon et al., 2007).  Both ischemia and 
reperfusion are responsible for myocardial injury and infarction, as the abrupt metabolic and 
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biochemical changes of reperfusion compound the damage by ischemia (Yellon et al., 2007) and 
these mechanisms will be discussed below.  Most importantly, ischemic and reperfusion 
damage are not homogeneous and numerous factors combine to produce the overall result of 
injury and infarction.  Common to both pathways of injury are calcium overload and oxidative 
stress, both of which can interact with numerous biological substrates, and are the main 
pathways of IRI (Piper et al., 2003).   
 
 
Figure 1: Ischemia reperfusion schematic of a Langendorff Heart, and respective mechanisms 
of ischemia reperfusion injury.  Abbreviations: ATP- adenosine triphosphate; Ca
2+
- calcium; 
mtPTP- mitochondrial permeability transition pore; pH- power of Hydrogen.  
Mechanisms of Ischemic Injury 
Myocardial ischemia results in a reduction of the oxygen and nutrients required by 
cardiomyocytes for normal performance, and ultimately survival.   Cellular homeostasis relies 
on regulation of energetic ATP supply; therefore under ischemic conditions aerobic production 
of ATP is severely reduced, and the cell relies heavily on anaerobic ATP production despite its 
inefficiency to produce ATP in comparison to aerobic metabolism (Hoffman et al., 2004).  The 
inefficiency of glycolysis is paired with a high output of inorganic phosphate, lactate, and H
+ 
(Cokkinos et al., 2006).  Under long durations of ischemia, anaerobic glycolysis is unable to 
provide sufficient energy, and combined with the resultant acidic conditions can cause damage 
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and death to cardiomyocytes (Cokkinos et al., 2006).  The time course of events during ischemia 
can be found in Table 1. 
 
Table 1: Time course of events during myocardial ischemia in an isolated rat heart 
TIME          EVENT  
1 - 2min ATP levels fall; cessation of contractility 
10 min 
~50% depletion of ATP; cellular edema, decreased 
membrane potential and susceptibility to arrhythmias 
20 - 24 min Irreversible cell injury 
 
 During ischemia, the impaired ATP synthesis rate causes imbalances in ionic state 
across cellular membranes, largely due to the inability of ATP-dependant pumps to function.  
Major contributors to the imbalance are the intracellular accumulation of sodium (Na
+
) and 
depletion of potassium (K
+
), which can cause osmotic swelling of the cell and damage to the 





 ATP dependant pump, and the activation of the sodium-hydrogen exchanger upon 
intracellular acidosis (Cokkinos et al., 2006).  The overall ion imbalance results in influx of 
calcium (Ca
2+
) through activation of voltage sensitive Ca
2+





 exchanger (Cokkinos et al., 2006).   The loss of high energy phosphates also leads 
to impaired sarcoplasmic reticulum (SR) Ca
2+
 uptake, allowing for even greater accumulation 
of cytosolic Ca
2+ 
(Cokkinos et al., 2006).    
The rise in cytosolic Ca
2+
 results in cellular damage by activation of Ca
2+
  dependent 
phospholipases, proteases, and calpains, causing membrane swelling, rupture,  in addition to 
ischemic contracture (Cokkinos et al., 2006; Ferdinandy et al., 2007).   Ischemic contracture is a 
consequence of the presence of Ca
2+ 
and lack of ATP within a cell, which results in non-
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cycling, attached actin-myosin crossbridges (Piper et al., 2003), and causes a distinct rise in left 
ventricular end diastolic pressure (LVEDP).  Contracture can results in cytoskeletal defects that 
render cardiomyocytes more fragile and susceptible to mechanical damage (Piper et al., 2003).   
In addition to disruptions in ionic homeostasis, cellular systems are overwhelmed by an 
increase in ROS production during ischemia.  Oxidative stress can cause damage to all 
components of a cell including lipids, proteins, and DNA, which exacerbates the dysfunction at 
the myocardium and causes both irreversible and reversible damage (Cokkinos et al., 2006).  
The major sources of ROS production during ischemia include the mitochondrial electron 
transport chain, xanthine oxidase, and the NADPH oxidase system (Cokkinos et al., 2006).  
ROS directly affect membrane enzymes, pumps and protein channels that are involved in the 
regulation of ion transport and lipid peroxidation, and can cause a change in membrane 
permeability (Buja, 2005).  Additionally, ROS can result in defective Ca
2+
 handling (Saini et 
al., 2005), and therefore add to the negative effects of ATP depletion on ion transport.  More 
specifically free radicals can impair Ca
2+ 
stimulated SR and sarcolemmal Ca
2+
ATPase activity, 
thereby reducing calcium transport into the SR or out of the cell, and exacerbating Ca
2+
 
overload within the ischemic cell (Netticadan et al., 1999; Bolli et al., 1999).  
Evidence reveals that SHR have increased susceptibility to ischemia which may be due 
to impairments in regulation of calcium handling, ion homeostasis, and energy metabolism 
(Galiñanes et al., 2004).  SHR with left ventricular hypertrophy exhibit faster onset and greater 
extent of ischemic contracture (Peyton et al., 1982; Anderson et al., 1987).  Energy metabolism 
is altered in SHR, with lesser ATP and creatine phosphate content during ischemia as 
compared to normotensive controls (Snoeckx et al., 1986; Anderson et al., 1990).  Reduced 
antioxidant potential (Batist et al., 1989)
 
 and increased intracellular Na
+
 accumulation during 
ischemia (Golden et al., 1994)
  
may also contribute to their increased susceptibility to ischemia.  
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Mechanisms of Reperfusion Injury 
Reperfusion of the ischemic environment is necessary in order to reoxygenate and 
salvage remaining viable tissue.  Restoration of blood flow to the previously ischemic 
myocardium results in mitochondrial reenergization, rapid restoration of pH, an increase in 
oxidative stress, inflammatory signaling, and intracellular Ca
2+
 overload, together which can 
lead to opening of the mitochondrial permeability transition pore (mtPTP), and 
hypercontracture (Yellon et al., 2007).  Although the pathogenesis of reperfusion injury is 
continually being investigated, the signaling pathways are complex and not completely 
understood. 
During reperfusion, mitochondria respond to the re-established delivery of oxygen and 
replenish energy stores that were lost during ischemia. By doing so the mitochondria produce 
high amounts of ROS, and leakage of ROS at the electron transport chain (Ferdinandy et al., 
2007; Ruuge et al., 1991).  The quick increase of oxygen in the acidic myocardium also favours 
the reaction of a hydroperoxyl radical, and this stress results in the decreased bioavailability of 
nitric oxide (Yellon et al., 2007).  High levels of ROS induce cellular damage to lipids, proteins, 
and deoxyribonucleic acid (DNA), can cause apoptosis (Becker, 2004), and can damage the SR, 
leading to Ca
2+ 
 leak (Yellon et al., 2007).  Additionally ROS attract neutrophils, and signal other 
inflammatory mediators, which can mediate cardiomyocyte death in the later stages of 
reperfusion (Yellon et al., 2007). 
Calcium plays an important role in the pathogenesis of reperfusion injury.  At 
reperfusion the high level of cytosolic Ca
2+
 from ischemia is compounded by the abrupt influx 
of Ca
2+
 through reenergized membrane transporters, and potentially by release of Ca
2+
 from  
damaged SR (Yellon et al., 2007), which provokes an uncontrolled myofibrillar activation (Piper 
et al., 2004).  The SR also begins to sequester excess Ca
2+
 upon reperfusion and when filled can 
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result in a cycle of Ca
2+
 uptake and release which requires excessive ATP usage without 
achieving calcium ion homeostasis (Hoffman et al., 2004).  In response to reperfusion, SHR 
exhibit a faster onset of Ca
2+ 
overload during reperfusion than normotensive rats (Friehs et al., 
2003).  The sustained high cytosolic Ca
2+
 levels can cause hypercontracture; a state of even 
greater LVEDP than during ischemia, and can induce cardiomyocyte death (Piper et al., 2004).  
Additionally, contracture can result in compression of microvessels within the myocardium, 
resulting in reduced perfusion (Piper et al., 2003).  
The mitochondria themselves are susceptible to reperfusion injury and can signal cell 
death via necrosis or apoptosis (Ferdinandy et al., 2007).  Apoptosis is an energy dependant event 
and prolonged ischemia results in energy depletion (Cokkinos et al., 2006).   Cell death occurs 
mainly by necrosis with some apoptosis in the early stages of reperfusion, and once energy 
stores are replenished, can transition to a larger proportion of apoptosis (Ferdinandy et al., 2007).    
The mtPTP is a nonspecific pore located between the mitochondrial membranes (Ferdinandy et 
al., 2007).  The mtPTP is signaled to open when there is an overload of Ca
2+
 in the 
mitochondrial matrix (Ferdinandy et al., 2007), and allows for release of apoptotic signalers 
(Yellon et al., 2007).  Additionally, opening of the mtPTP causes swelling of the mitochondria 
due to influx of electrolytes and water, and subsequent loss of membrane potential (Ferdinandy 
et al., 2007).  Other metabolic changes that occur during reperfusion, including the restoration 
of pH due to the washout of H+ and the buildup of ROS, favour opening of the mtPTP (Yellon 
et al., 2007).  Cell death caused by opening of the mtPTP is a result of either apoptosis, proving 




Protection of the myocardium against IRI is imperative as loss of myocardial function 
is the key factor responsible for cardiovascular morbidity and mortality.  With increasing 
emphasis on preventing and treating chronic disease through nutritional modification, further 
exploration has resulted in the use of nutraceuticals to improve tolerance to IRI.  By producing 
a state of cellular protection, nutraceuticals reduce the injury from ischemia, and manipulate 
the response to reperfusion.   
One of the recently popular cardioprotective agents being studied is resveratrol.  The 
first reports on resveratrol as a cardioprotective agent showed its potential to directly protect 
isolated hearts from IRI (Ray et al., 1999).  Recent studies using acutely treated hearts establish 
that the mechanisms of cardioprotection provided by resveratrol mimic certain pathways 
common to ischemic preconditioning (Ray et al., 1999; Hattori et al., 2002; Das et al., 2005; 
Bradamante et al., 2004).   These include pathways relating to inflammation, K
+
 dependant ATP 
channels, oxidative stress, and apoptosis, and will be discussed below.    
Resveratrol as a Cardioprotective Agent 
Resveratrol, 3,5,4’-trihydroxystilbene, is a plant-derived polyphenol found in dietary 
sources such as grape skin, peanuts, and red wine (Wenzel et al., 2005).  It is thought to play a 
significant role in the French Paradox, an observation that there is a low incidence of 
cardiovascular disease in the French population despite having a diet high in saturated fats 
(Kopp, 1998).  Purified resveratrol is currently being sold in supplemental form as a 






Figure 2: Structure of Resveratrol 
 
 Resveratrol is well absorbed and distributed to organs in both rodents and humans.  It 
is metabolized primarily to glucuronide and sulfate conjugates, though the biological activity 
of these metabolites remains unknown (Wenzel et al., 2005).  Additionally resveratrol is capable 
of binding to human serum albumin and hemoglobin (Lu et al., ).  Resveratrol is detectable in 
plasma 15 minutes after oral administration, whether it is ingested from red wine or as a 
supplement, and peak plasma concentrations are reached around 30-60 minutes post ingestion 
(Wenzel et al., 2005).  A secondary peak occurs 6 hours post ingestion, suggesting release from 
hemoglobin, or reabsorption of conjugated metabolites from the intestine (Wenzel et al., 2005).   
Cardioprotective agents attempt to reduce irreversible cell death, and promote a safe 
transition to normal contractile function following ischemia.  Numerous studies using 
normotensive isolated rat hearts elucidate the cardioprotective abilities of resveratrol against 
IRI with both chronic and acute treatment.  Acute resveratrol treatment refers to the in vitro 
direct application of resveratrol to an isolated heart through perfusate, and chronic treatment 
refers to the in vivo treatment of an animal for several days before the heart is removed.  
Difficulty arises when attempting to apply the results of acutely treated isolated hearts 
undergoing IR to a clinical setting as one is unable to predict an ischemic occurrence.   Chronic 
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ingestion of resveratrol in wild type rats affords greater functional recovery to isolated hearts 
undergoing IR as compared to acute treatment (Dernek et al., 2004; Bradamante et al., 2003), 
though currently the dosages used greatly exceed even the supplemental dose available to 
humans.  It is therefore of importance to understand the cardioprotective effects of chronic 
resveratrol treatment using doses that would be attainable to humans. 
At varying doses and delivery methods, resveratrol reduces IRI as evidenced by 
reduction of infarct size, reduction in apoptotic cardiomyocytes, and greater recovery of left 
ventricular contractility (Das et al., 2006).  Resveratrol acts to attenuate myocardial ischemia-
reperfusion injury (Das et al., 2006; Goh et al., 2007) by affecting multiple pathways including 
inflammation, oxidative stress, potassium channels, and apoptosis.  These pathways are targets 
for protection against IRI (Turer et al., 2010), and furthermore these pathways are disrupted in 
the SHR (Yuhki et al., 2010; Lassègue et al., 2004; Cameron et al., 1988; Peng et al., 1999).  
Additionally, chronic resveratrol treatment for protection against IRI in hypertensive rats has 
not yet been studied.  Altered characteristics of these pathways in SHR animals, and lack of 
research relating resveratrol to IRI in SHR, provide basis for chronic treatment with resveratrol 
in SHR.  The mechanisms of cardioprotection provided by resveratrol in normotensive animals 
will be discussed below, though the examination of pharmacologic cardioprotection by 









Inflammation is a property of atherosclerosis, is exacerbated by hypertension, and can 
cause MI (Ogita et al., 2004).   Resveratrol possesses anti-inflammatory properties linked to its 
ability to inhibit the synthesis and release of pro-inflammatory mediators (Das et al., 2007), 
inhibit platelet aggregation and proadhesive molecules, and prevent endothelial disruption 
during IR (Shigematsu et al., 2003; Das et al., 2006).  Additionally, resveratrol inhibits pro-
inflammatory mediator-related enzymes such as cyclooxygenase in arteries (Das et al., 2007).  
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Resveratrol therefore provides cardioprotection by reducing tissue injury by inflammatory 
mediated pathways of the vasculature.   
The use of a COX inhibitor, such as Aspirin, is often recommended at the onset of 
myocardial ischemia (Trialists' Collaboration, 1994), but the effects of COX inhibition in 
cardiomyocytes during IRI is not well understood.  Recent data suggest that although there are 
benefits to blocking COX in the arteries to prevent inflammatory signaling, there may be a 
cardioprotective role played by activated COX in cardiomyocytes during IRI (Camitta et al., 
2001).   This protection exists when COX-2 is stimulated by NO under ischemia reperfusion 
conditions (Bolli et al., 2002), and when COX-2 is constitutively expressed (Inserte et al., 2009).  
Additionally, COX-1 and COX-2 null mice demonstrate reduced tolerance to IRI (Camitta et al., 
2001; Yuhki et al., 2011).  Ventricular tissue from animals treated for 14 days with 2.5mg 
resveratrol/Kg of body weight/day demonstrate no change in COX-1 expression, but a large 
increase in COX-2 expression (Dudley et al., 2008).   The differences between SHR and WKY 
myocardial COX expression is not yet known, though the association of prostanoids with 
hypertension and cardiac hypertrophy would suggest there may be differences (Yuhki et al., 
2010).   
Antioxidant Activity 
Antioxidants and free radical scavengers have favorable effects on both hypertension 
and IRI.  Oxidants are able to elicit an inflammatory response, calcium overload, and apoptotic 
signaling (Zhao, 2004).  Resveratrol works as a powerful antioxidant in vivo by direct and 
indirect mechanisms including scavenging of free radicals, and enhancement of oxidative 
enzyme expression (Das et al., 2006).  Resveratrol directly scavenges peroxyl, hydroxyl, and 
superoxide radicals (Ray et al., 1999), and reduces malonaldehyde formation in the 
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postischemic reperfused myocardium (Das et al., 2006).  Additionally, oxidation of low density 
lipoprotein (LDL), which is strongly associated with coronary heart disease and MI (Holvoet, 
2004), is inhibited by resveratrol treatment in humans (Frankel et al., 1993).  Reduction of 
LDL oxidation by resveratrol may act as a preventative measure against atherosclerotic plaque 
formation, and subsequent MI. 
A large component of resveratrol’s antioxidant nature arises from the ability to increase 
nitric oxide synthesis at rest and during ischemia reperfusion in the isolated heart (Hattori et 
al., 2002).  In the myocardium, release of NO results in inotropic and chronotropic events, 
including enhancement of ventricular relaxation, and decreased myocardial O2 consumption, 
and the upregulation of iNOS and eNOS is a factor involved in preparing the heart’s defenses 
against IR (Bolli, 2001).   Chronic resveratrol treatment at 0.5-2.5mg/Kg/day-i.p. upregulates 
eNOS and iNOS expression, in addition to increasing NO bioavailability by directly 
scavenging free radicals, and stimulating NO production (Hung et al., 2004; Bradamante et al., 
2004; Das et al., 2005).  The use of acutely treated isolated hearts with 10uM resveratrol from 
iNOS knockout mice (Imamura et al., 2002), and use of the NO antagonist N
G
-nitro-L-arginine 
methyl ester (L-NAME) in both an acute (10uM) and chronic (25mg/L for 15 days) setting 
(Bradamante et al., 2003) during IR abolishes the cardioprotective effects of resveratrol.  This 
confirms the role of NOS in resveratrol induced cardiac protection.   
  Myocardial mitochondria also play an important role during IR as dysfunction and 
production of mitochondrial ROS contribute to cardiac failure and cell death.  Recently 
resveratrol has been shown to increase mitochondrial NO (mtNO), and reduce mitochondrial 
lipid peroxidation which may act to decrease the ROS leak from the mitochondria (Gutiérrez-
Pérez et al., 2011).    
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  SHR possess elevated reactive oxygen species and markers of oxidation (Lassègue et 
al., 2004), and at 18 weeks of age have reduced eNOS expression in the left ventricle (Piech et 
al., 2003).  The mitochondrial of SHR are susceptible to the elevation in oxidative stress, 
resulting increased mitochondrial damage and dysfunction (Ballinger, 2005).  Additionally, 
lipid peroxidation in the SHR myocardium is elevated (Torii et al., 1992).  SHR receiving 
2.5mg/Kg/day of resveratrol by oral gavage for 10 weeks have reduced oxidative stress and 
recovered levels of antioxidants in the myocardium (Thandapilly et al., 2010). The above 
characteristics of SHR, and the antioxidant effects of resveratrol provide basis for studying 
resveratrol treatment in SHR against IRI.   
ATP Dependant Potassium Channels 
Activation of ATP dependent potassium channels (KATP) is an adaptive mechanism that 
provides protection from IRI (Grover et al., 2000), and is common to the ischemic 
preconditioning pathway (Cole et al., 1991).  Initially it was found that as ATP levels within a 
cell decline, the KATP open, though it is now known that other endogenous factors including pH 
and NO, as well as pharmacologic agonists, are able to stimulate opening the KATP (Grover et 
al., 2000).  The use of various KATP openers during IR reduces necrosis and improves 
functional recovery of an isolated heart (Grover et al., 2000).  Opening of KATP during IR 
results in reduced action potential duration, and therefore reduced Ca
2+
 entry via voltage-
dependant Ca
2+
 channels (Grover et al., 2000).  
Resveratrol is able to enhance KATP  activation in isolated cardiomyocytes receiving 0.1-
100umol/L of resveratrol (Chen et al., 2008; Goh et al., 2007), though research in this area of 
study is lacking with respect to stressed conditions such as IR.  KATP are involved in the 
protection against IRI by red wine extract, likely through PKC activation (Mosca et al., 2002).  
Additionally, it is well established that in SHR cardiomyocytes, KATP sensitivity to ATP is 
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reduced (Cameron et al., 1988) and together with the above suggests the relevance of KATP in 
resveratrol induced cardioprotection on hypertensive animals. 
Apoptosis 
Resveratrol provides cardioprotection against IRI by attenuating the number of 
apoptotic myocytes.  Apoptosis can occur during the ischemic phase, be triggered at 
reperfusion, or accelerated by reperfusion (Cokkinos et al., 2006; Zhao, 2004).  Apoptosis is 
upregulated in SHR cardiomyocytes (Peng et al., 1999), and SHR may therefore benefit from 
treatment with resveratrol.  Resveratrol enhances pro-survival signaling.  Activation of 
adenosine receptors A1 and A3, by acute administration of 10uM resveratrol to isolated hearts, 
leads to survival signaling by Bcl-2, and decreased apoptotic signaling by Bad via an Akt 
pathway and cAMP response-element binding protein (CREB) (Das et al., 2005).  This pathway 
can also lead to stimulation of NO production by Akt phosphorylation (Das et al., 2005).  
Further to this, in studies using both acute (10uM) administration to isolated hearts and chronic 
gavage (2.5mg/Kg/day for 7 days), resveratrol activates a mitogen-activated protein kinase 
(MAPK) pathway to activate extracellular signal-regulated kinase (ERK) 1 and 2, and p38α 
MAPK (Das et al., 2006; Das et al., 2006).  This activation acts as a part of the signaling pathway 
via CREB, resulting in survival signaling via Bcl-2 (Das et al., 2006). 
As previously mentioned, opening of the mtPTP can occur during reperfusion, causing 
release of apoptotic stimuli and swelling of the mitochondria.  Chronic resveratrol treatment 
(2.5mg/Kg/day for 14 days by gavage) reduces mitochondrial swelling during reperfusion, 
which is presumed to lead to the resultant reduction in cell death (Dudley et al., 2008). 
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Resveratrol and Hypertension 
In SHR animals, resveratrol treatment has primarily been used to study the treatment of 
hypertension and LV hypertrophy.  Previous research from this lab, using chronic dietary 
resveratrol treatment at physiologically relevant doses, showed improved vasorelaxation in 
aorta of SHR animals (Rush et al., 2007).  Additionally, chronic resveratrol treatment for 10 
weeks, at 2.5mg/Kg/day by oral gavage,  prevents the development of pathological cardiac 
hypertrophy and contractile dysfunction in SHR (Thandapilly et al., 2010), though at present 
there is a lack of evidence regarding the effects of pharmacologic cardioprotection with 
resveratrol on SHR.  Because of alterations in SHR myocardial pathways that are related to the 
pathways cardioprotection provided by resveratrol in normotensive animals, it is of interest to 
















PURPOSE OF STUDY 
 
The above provides background regarding IRI and the potential for resveratrol to act as 
a powerful cardioprotective agent in both normotension and hypertension.  This, taken together 
with the lack of research on chronic resveratrol treatment and IRI in hypertensive individuals, 
provides rationale for the current study.  Also described above are the mechanisms by which 
resveratrol counteracts the detrimental effects of hypertension on various systems of the heart.  
The interaction of resveratrol on hypertension-induced changes to the myocardium may have a 
beneficial effect on IRI.  Of interest to this study is whether a dietary or supplemental amount 
of resveratrol is required to evoke cardioprotection. We will treat animals by providing 
resveratrol in the drinking water at two different doses.  The first dose will mimic the resveratrol 
content one could ingest through moderate red wine consumption (Low), and the second dose will 
mimic the resveratrol amount that one could ingest through daily supplemental consumption (High).   
The purpose of this study is to investigate the cardioprotective effects of chronic 
resveratrol treatment against myocardial infarction and post ischemic dysfunction, in 
hypertensive and normotensive animals, using functional and biochemical parameters.  
Secondary to this we will assess baseline protein expression in SHR and WKY after resveratrol 
treatment at both doses.  
The expression of many different proteins is negatively susceptible to hypertension, and 
the expression of these same proteins also can be positively altered by resveratrol treatment.  In 
addition these proteins are known to play a role in IRI.  We will therefore assess the effect of 







1. SHR animals will show greater functional susceptibility to IRI, and infarct size than 
WKY 
2. Chronic resveratrol treatment will protect against post ischemic dysfunction in both 
SHR and WKY animals 
3. Chronic resveratrol treatment will decrease myocardial infarct size in both SHR and 
WKY 
4. Resveratrol treatment at a high dose will provide greater cardioprotection than at a low 
dose in both SHR and WKY animals 
Secondary Hypotheses 
 Hypertension will negatively affect protein expression, and resveratrol treatment will 












Experiments were performed using a total of 78 male WKY (n= 39) and SHR (n=39) 
rats, obtained from Harlan (Indianapolis, IN) at the age of 13 weeks.  Animals were group 
housed at a constant air temperature (20-21°C), and humidity (~50%) in a 12h:12h reverse 
light-dark cycle.  Animals had access to standard 22/5 (W) Rodent Diet lab chow and tap water 
until 16 weeks of age at which point they began the resveratrol (trans-3,4’,5-
trihydroxystilbene) treatment stage  and were housed individually.   
Treatment 
At 16 weeks of age animals began the 4 week treatment protocol ingesting tap water 
containing 1g/100ml low viscosity carboxymethylcellulose and one of the following; 
6.361mg/100mL Resveratrol (High), 0.06361mg/100mL Resveratrol (Low), or no Resveratrol 
(Control) (Toronto Research Chemicals, Ontario).   Consumption was measured on a 24 hour 
basis, and drink was prepared and replaced daily under dim light conditions.  Bottles were 
wrapped in tin foil to create a light-negative container environment, which prevented 
resveratrol decomposition.   
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Isolated Heart Preparation 
 
Figure 4: Retrograde flow through an isolated heart.  Perfusate (represented by the arrows) 
begins at the coronary ostia, flows through the coronary tree into the myocardium, and exits 
through the coronary sinus and right atrium.   
 
The Langedorff technique uses an isolated heart to maintain cardiac activity and 
permits for the measurement of left ventricular functional parameters and coronary vasomotor 
function.  The heart is perfused in a retrograde fashion, causing the aortic valve to remain 
closed, forcing perfusate through the coronary system, and out through the coronary sinus and 
right atrium (Figure 3).  Hearts remain stable without an appreciable decline in function for up 
to 4 hours (Figure 7).   
Aortic Cannula 
Left Coronary Artery 
Left Ventricle 
Right Ventricle 




Figure 5: Schematic of the Langendorff Isolated Perfused Heart Set Up.   
 
At 28 days of treatment body mass was recorded and a thoroacotamy was performed 
under anesthesia by pentobarbital sodium injection (40-50mg/Kg intraperitoneally [i.p.]).  Rats 
first underwent invasive carotid artery blood pressure and flow measurement prior to 
thoroacotamy to confirm a hypertensive or normotensive state, though the procedure is not part 
of this study.  Hearts were excised, arrested in 4°C modified Krebs Heinsleit buffer (KHB) 
(118mM NaCl, 4.7mM KCl, 1.25mM CaCl2*2H2O, 1.2mM MgSO4*7H2O, 1.1mM KH2PO4, 24mM NaHCO3, 
10mM Glucose), and cannulated to a Langendorff constant flow apparatus at the aorta.  Hearts 
were perfused in a retrograde fashion using oxygenated (95%O2/5%CO2), normothermic 
(37°C) KHB.  Using an ultrasound probe, flow rate was set to mimic an in vivo flow rate by 
using an equation which estimates coronary flow (CF) from heart weight (Döring, 1990) using 
the equation CF = 7.43*HW
0.56
, and heart weight from body weight using the equation 
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HW=(BW*0.0027)+0.6.  A fluid filled balloon connected to a pressure transducer was inserted 
into the left ventricle through an incision in the left atria and inflated to an end diastolic 
pressure of 7-10mmHg to monitor and record left ventricular function. A second pressure 
transducer was connected to the perfusate flow line just above the heart to record coronary 
perfusion pressure.  An ultrasonic probe measured flow of perfusate into the heart.  Coronary 
perfusion pressure (CPP), heart rate (HR), coronary flow rate, left ventricular systolic and end 
diastolic pressure (LVSP, LVEDP), and rate of pressure development (+dP/dt) were recorded.  
Langendorff hearts completed one of two procedures; an ischemia-reperfusion protocol, or a 20 
minute stabilization protocol as outlined below.  During stabilization hearts were inspected for 
exclusion criteria as depicted in Table 2.  
Parameter Criteria 
Time to perfusion from excision (min) >2 min 
Heart Rate <100bpm,  >400bpm 
Left ventricular developed pressure <70mmHg 
Table 2: Exclusion criteria for the Langendorff perfused rat hearts. Any criteria residing 
outside of these values suggests damage to an isolated heart during excision and cannulation. 
Langendorff Protocol 
All hearts underwent a 20 minute stabilization period.  Prior to this hearts were cleared 
of fat and the left ventricular balloon was allowed to equilibrate to the temperature of the 
ventricle. After stabilization, 10 hearts from each group underwent 30 minutes of no flow 
ischemia, followed by 2 hours of reperfusion at the original flow rate.   These hearts were then 
removed from the Langendorff, weighed, and frozen for infarct size measurement.  A subset of 
3 hearts from each group completed only the 20 minute stabilization protocol to flush blood 






Figure 6:  Langendorff isolated perfused heart protocols 
 
The reperfusion period of 2 hours was chosen in order for effective washout of 
dehydrogenases, and therefore accurate infarct size staining (Schwarz et al., 2000), as well as 
to capture emergence from stunning, should stunning be apparent in our study.   In order to 
establish viability of the preparation, we perfused isolated hearts from WKY and SHR animals 
for 3 hours (the maximal duration of our Langendorff protocol).  As shown in Figure 6 there is 
a small, if any, decline in contractile function after 3 hours of isolation and perfusion.  Two 
hearts from each group, and only one from WKY High were excluded from the study as they 
presented one or more exclusion factor as in Table 1, or they presented sustained fibrillation at 
reperfusion.   
 
Figure 7: Contractility of Isolated Perfused Hearts over 3 Hours of baseline perfusion. Each 
group represents the average of 2 hearts.  Abbreviations: SHR-spontaneously hypertensive rat, 























Infarct Size Measurement 
At the end of reperfusion the hearts were excised, trimmed of remaining aorta and atrial 
appendage, and stored at -70°C sealed in plastic wrap and tin foil for future processing.  Frozen 
hearts were sliced transversely from base to apex in 1mm slices using a razor blade.  The slices 
were thawed at room temperature, blotted, and incubated in 1% wt/vol triphenyltetrazolium 
chloride (TTC) in a phosphate buffer solution at 37°C for 20 min.  The slices were flipped after 
10 min of incubation, and the containers were agitated at 5 min intervals.  Slices were then 
blotted, fixed between 2 cover slides spaced at 1mm, and imaged using a dissection microscope 
and a digital camera.  Infarct size was quantified using NIH Image 5.1 by dividing each image 
into ischemic but viable (TTC stained) and infarcted (TTC negative) zones.  The total area 
(Figure 7A) and total infarct area (Figure 7B) of each slice was calculated and converted to 
millimeters squared.  Volume was then calculated using the known thickness of 1mm.   Total 
heart volume was quantified by adding slice volumes together, and total infarct volume of the 
heart was found by the sum of the slice infarct volumes.  Infarct size was then quantified as a 




Figure 8: TTC Staining of a Heart Slice.  Images do not represent slices from this study.  A. 
Total heart area is outlined.  B. Total infarct area is outlined.  Infarct size is quantified as a 
ratio of infarcted area (B) to total slice area (A).   
 
Western Blot Analysis  
As described above, a separate set of hearts from each group (n=3 per group) were 
removed from the Langendorff apparatus following a 20 min stabilization period to assess 
protein expression.  Hearts were cut into left and right ventricles, weighed, and the free wall of 
the left ventricle was excised and snap frozen in liquid nitrogen. Left ventricular tissue was 
hand homogenized at 0°C using Urea buffer containing phosphatase and protease inhibitors.  
Upon centrifugation, aliquot of homogenate, and heating of homogenate at 60°C for 3 hours, 
samples were denatured for 5 min at 95°C.   30µg of protein was loaded per well alongside 
14µL biotin and 14µL rainbow biotin for molecular weight identification, and was resolved by 
SDS-PAGE (120V) and transferred to a polyvinylidene fluoride membrane (50V, 25min).  The 
membrane was blocked in 5% Bovine Serum Albumin in 10mM Tris-HCL, 0.5M NaCl, 0.5% 
Tween 20, pH 7.4, for 1 hour at room temperature.  The primary buffers were applied and 
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incubated for 12 hours at 4°C, or 1 hour at room temperature.  After a washing cycle using 
10mM Tris-HCL, 0.5M NaCl, 0.5% Tween 20, the membranes were incubated in the original 
block solution with the addition of secondary antibodies for 1 hour at room temperature.  The 
membranes then underwent a second washing cycle and were imaged using enhanced horse-
radish peroxidase chemiluminescence reagent on a SynGene (ChemiGene
2
).     
Statistical analysis 
Values in this document are presented as mean±SEM, with n referring to the number of 
animals per group.  Area under the curve was analyzed using a trapezoid method, and infarct 
size analysis using Image J (public domain NIH software).  All results underwent two way 
ANOVA using SAS and Statistica 8.0 statistical software, and statistically relevant 
comparisons were tested using Tukey-Kramer HSD post hoc, and expected to reach a 












On average, across all treatment groups WKY animals are leaner than age-matched 
SHR (318.3±4.0 vs 344.1±3.9 g, p<0.001), which corresponds with lesser food (491.5±4.8 vs 
532.6±4.9 g, p<0.001) and drink consumption (35.0±0.7 vs 47.2±0.7 mL/day, p<0.001) over a 
4 week period.  Treatment with resveratrol did not affect body weight or consumption levels 
(Table 3).  The change in BW over 4 weeks did not differ among strain or treatment group 
(Table 3).  Due to sacrifice of 1 animal per day, ages at the time of sacrifice ranged between 
20-22 weeks.   
Increased drink consumption corresponds to an increased resveratrol intake by SHR 
animals as compared to WKY in both treatment groups (Table 3).  Consumption of resveratrol 
in the Low groups (WKY- 0.022mg/day, SHR- 0.030mg/day) was ~100 times less than in the 
High groups (WKY-2.02mg/day, SHR-2.79mg/day).  As planned, when weight adjusted to the 
size of a 70Kg human, consumption in the Low group mimicked the resveratrol content in 
daily moderate red wine intake (~5.5mg/day), and in the High group mimicked the resveratrol 
content of supplemental intake (~508mg/day).    
As expected, across strain, SHR animals show greater indices of left ventricular 
hypertrophy than WKY which is evidenced by an increased heart weight to body weight ratio 
(4.44±0.09 vs 3.89±0.10 mg/g, p<0.001), and increased left ventricular weight to body weight 
ratio (3.21±0.09 vs 2.75±0.09 mg/g, p<0.01).  On average across treatment groups, Low 
resveratrol treatment significantly reduced heart weight as compared to Control (1.30±0.05 vs 
1.46±0.04g, p<0.05); however, treatment with resveratrol did not affect other indices of 
hypertrophy including HW:BW and LVW:BW of either strain (Table 4).   
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Baseline Myocardial Contractility Data 
In isolated hearts, all groups stabilized to a similar level of HR, left ventricular end 
diastolic pressure (LVEDP), left ventricular developed pressure (LVDP), and maximal rate of 
pressure development (+dP/dt) (Table 5).  No strain, drug, or interaction effects exist.  
Baseline Coronary Parameters 
All coronary parameters were first analyzed unnormalized, and then normalized to BW 
to account for the appropriate setting of flow based on BW.  Subsequently all coronary 
parameters were normalized to HW to allow for analysis per gram of heart tissue. Baseline 
coronary flow rates were higher in SHR animals, due to the setting of flow based on body 
weight (Table 6). When normalized to BW and to HW, coronary flow did not differ by 
treatment group or strain (Table 6).  
 Coronary perfusion pressure is a measure of the pressure gradient between the aorta and 
the right atrium.   CPP at baseline was higher in SHR animals compared to WKY across all 
treatment groups, and this effect is abolished when normalized to HW (Table 6).   
Strain and treatment did not affect other baseline parameters including coronary 
vascular resistance (CVR) and coronary vascular conductance (CDT), though differences 
emerged when normalized to HW.  Across strain groups, when normalized to HW, CVR and 
CDT were affected by strain (Table 6). SHR animals had a higher level of CVR than WKY 
(9.9±0.46 vs 7.9±0.44 mmHg.min/mL/g p<0.01), and CDT was lower in SHR animals 
compared to WKY (10.9±0.5 vs 13.3±0.5 mL.min/mmHg/100g p<0.01).  Interestingly, CDT 
was significantly lower SHR Control and Low hearts as compared to WKY Low, when 
normalized to HW (9.7±0.9 and 10.1±1.1 vs15.6± 0.9 mL.min/mmHg/100g  p<0.01).  In 
contrast, High resveratrol treatment increases conductance per gram of HW in SHR, to levels 




Across treatment groups, Figure 9 depicts a main effect of treatment, as evidenced by 
reduction in infarct size in both High and Low treated hearts as compared to Control hearts 
(19.9±0.9 and 19.4±0.8 vs 27.7±0.9 % of infarcted volume/total volume p<0.001).  No strain or 
interaction effects exist. 
Ischemia Reperfusion Myocardial Functional Parameters 
AUC analysis was completed in attempt to tease out strain differences in cardiac 
functional parameters during reperfusion and ischemia.  It should be stated that significant 
differences between groups for AUC analysis were less evident as AUC analysis takes into 
account variability among subjects for multiple time points, making the variability of AUC 
analysis between groups large.  For LVDP and +dP/dt, AUC has been calculated by subtracting 
the area of 2 hours of baseline activity from the 2 hour reperfusion area to calculate change in 
area under the curve from baseline (∆AUC).   
LVEDP, a measure of contracture of the left ventricle, is maintained around baseline 
values during reperfusion by both High and Low resveratrol treatment, when analyzed on an 
individual time point basis (Figure 10).  No strain differences or interaction effects exist.  
Interestingly resveratrol treatment at both a High and Low dose reduces the variability among 
subjects as compared to the Control group, and this holds true for both strains (Figure 10).  
During reperfusion, AUC for LVEDP is reduced in hearts treated with Low resveratrol as 
compared to the Control group, indicating less contracture with Low resveratrol treatment 
(Figure 11b).   
Left ventricular developed pressure is normalized to baseline values in order to 
represent the percent change from baseline of an individual heart. During the early stages of 
reperfusion, a drug effect was not apparent (Figure 12).  However, during the late stages of 
reperfusion, both the High and Low resveratrol treated hearts demonstrated significantly 
improved contractility as compared to Control hearts (Figure 12).  This represents a stronger, 
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more protected functional response to ischemia reperfusion injury in the treated groups as 
compared to the Control.  No strain differences or interaction effects exist.  During reperfusion, 
the ∆AUC for LVDP is lesser in the High group as compared to the Control group (Figure 13).  
This represents less impaired left ventricular contractility during reperfusion with High 
resveratrol treatment.   
Maximal rate of pressure development is normalized to baseline values in order to 
represent the percent change from baseline during reperfusion. During the early stages of 
reperfusion only the High resveratrol treatment group significantly protected against a decline 
in rate of pressure development (Figure 14).  At the late stages of reperfusion both the High 
and Low resveratrol treatment significantly maintained +dP/dt as compared to no treatment 
(Figure 14).  This represents a greater functional tolerance to ischemia reperfusion injury in the 
resveratrol treated hearts as compared to the Control hearts.  No strain differences or 
interaction effects were found.  ∆AUC for +dP/dt during reperfusion showed no strain 
differences.  Both High and Low resveratrol treatment maintained ∆AUC around baseline 
+dP/dt, as compared to the Control group which had a large negative ∆AUC from baseline 
(Figure 15).  This represents a reduction in +dP/dt in the Control group, and improvement of 
+dP/dt by resveratrol treatment during reperfusion.  
Coronary Parameters During Reperfusion 
Resveratrol treatment did not affect any coronary parameters during reperfusion, 
though strain differences exist. 
Coronary flow during reperfusion was matched to basal flow rate and did not differ 
among groups when normalized to BW or HW.  Coronary perfusion pressure did not show any 
effects of treatment or strain at 30 and 2 hours of reperfusion.  This remained true when 
normalized to BW and HW.   
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Across strain groups, after 30 minutes of reperfusion CVR was lower in WKY animals 
as compared to SHR when normalized to HW (9.7±1.0 vs 12.8±0.9 mL.min/mmHg/100g  
p<0.05).  No effects of drug or strain were apparent at 2 hours of reperfusion.  
At 30 minutes of reperfusion CDT was higher in the WKY animals as compared to 
SHR when normalized to HW (10.8±0.4 vs 8.9±0.5 mL.min/mmHg/100g  p<0.01) which 
mimicked the strain effect at baseline.  By two hours of reperfusion the strain effect was 
abolished, and drug effects were not apparent (Table 7). 
Western Analysis 
Cyclooxygenase -1 
As depicted in Figure 16 COX-1 protein expression is reduced by resveratrol treatment.  
Low resveratrol treatment significantly reduced COX-1 protein expression in both WKY and 
SHR as compared to Control. High resveratrol treatment depicts a reduced, but not 
significantly lower level of COX-1 protein as compared to Control.  No strain differences exist. 
Cyclooxygenase-2 
Western blot analysis revealed a reduced level of COX-2 protein expression in SHR 
Con compared to WKY Con (0.76±0.06 vs 1.0±0.01 normalized arbitrary units, p<0.001) at 
baseline.  In WKY, Low resveratrol treatment significantly reduced COX-2 expression, though 
High resveratrol treatment did not affect protein expression (Figure 17).  In SHR, Low 
resveratrol treatment did not affect COX-2 protein, but High resveratrol significantly reduced 
COX-2 protein as compared to Control (Figure 17).   
AMP Activated Protein Kinase 
Western blot analysis for AMPK protein expression revealed no strain differences.     
AMPK expression in WKY High is significantly higher than all groups except WKY Low 




Western blot analysis for phosphorylated-AMPK (pAMPK) protein expression revealed 
no strain differences or interactions (Figure 19).   Across treatment groups, Low resveratrol 
treatment resulted in significantly higher pAMPK protein expression compared to the High 
treatment group (1.13±0.09 vs 0.92±0.10 arbitrary normalized units p<0.01).   
Ratio of Phosphorylated AMPK to AMPK 
 No main or interaction effects were found for the ratio of p-AMPK to AMPK, as 
demonstrated in Figure 20.  
Endothelial Nitric Oxide Synthase 
Western blot analysis of eNOS protein at baseline revealed lowered protein expression 
in SHR Con compared to WKY Con (0.67±0.007 vs 1.0±0.01 arbitrary normalized units 
p<0.0001).  Interestingly resveratrol treatment did not affect eNOS protein levels in WKY 
animals, but in the SHR, High resveratrol treatment increased protein expression of eNOS, 
which was significantly higher than all other groups (Figure 21).   
Phosphorylated Endothelial Nitric Oxide Synthase 
Across treatment groups, as depicted in Figure 22, High resveratrol treatment 
significantly increases phosphorylated eNOS protein as compared to both Control and Low.  
No strain differences exist. 
Ratio of Phosphorylated eNOS to eNOS 
An interaction between strain and treatment exists for the ratio of activated to 
unactivated eNOS.  WKY High hearts have an increased proportion of activated to unactivated 
eNOS as compared to WKY Con, and WKY Low, whereas SHR High animals show reduction 
in the ratio as compared to SHR Con and SHR Low (Figure 23).  Additionally, SHR Con and 
Low animals have a larger ratio of activated to unactivated eNOS as compared to WKY Con 
(Figure 22).   
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Cytochrome C  
Western blot analysis of cytochrome C protein expression revealed no differences 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 9: Myocardial Infarct Size.  Calculated as a ratio of infarcted tissue (pale peach/white) 
to total tissue volume (red), as determined by TTC staining on hearts that underwent 30 min 



































































Figure 10: LVEDP curve during stabilization, ischemia, and reperfusion.  Values represent means ± 
S.E.M.*p<0.05 High and Low vs Con, #p<0.05 Low vs Con. Abbreviations: LVEDP-left ventricular 
end diastolic pressure; Con-control. 
Figure 11: Area under the curve for LVEDP.  A. Area under the curve for LVEDP during 30 mins 
ischemia. B. Area under the curve for LVEDP during 2 hours reperfusion.  Values represent means ± 
S.E.M.  *p<0.05 Low vs Con.  Abbreviations: LVEDP-left ventricular end diastolic pressure; Con-















Figure 13 Change in area under the curve from baseline for LVDP during 2 hours of 
reperfusion.  Baseline area under the curve for 2 hours of reperfusion was subtracted from 
each condition. Values represent means ± S.E.M *p<0.05 High vs Con.  Abbreviations: LVDP-
left ventricular end diastolic developed pressure; Con-control; ∆AUC- change in area under 
the curve from baseline 
Figure 12: LVDP during stabilization, ischemia, and reperfusion. All data points are normalized 
to their respective baseline values, and represent means ± S.E.M. The dashed line represents the 
baseline in which AUC was calculated from in the subsequent figure.  *p<0.05 High and Low vs 









Figure 14: Maximal rate of pressure development.  All data is normalized to its respective 
baseline value. Values represent means±S.E.M. The dashed line represents the baseline in 
which AUC was calculated from in the subsequent figure.  *p<0.05 High and Low vs Con, 











Figure 15: Area under the curve for rate of pressure development during 2 hours of 
reperfusion.   AUC of baseline across 2 hours of reperfusion was subtracted from each 
condition. Values represent means ± S.E.M *p<0.01 vs Con.  Abbreviations: LVDP-left 
ventricular end diastolic developed pressure; Con-control; ∆AUC- change in area under the 














































































































































































































































































































































Figure 16: Western blot analysis of COX-1 protein.  All values are normalized to WKY Con.  
COX-1- cyclooxygenase-1.  Values represent means ± S.E.M of densiometry analyses.  
*p<0.01 vs Con. Abbreviations: COX-1-cyclooxygenase 1; Con- control; SC- SHR Con; SL-


















Figure 17: Western blot analysis of baseline COX-2 protein.  All values are normalized to 
WKY Con.  Values represent means ± S.E.M of densiometry analyses.  *p<0.01 vs WKY Con or 
WKY High. Abbreviations: COX-2-cyclooxygenase 2; Con- control; SC- SHR Con; SL-SHR 
Low; SH-SHR High; WC-WKY Con; WL-WKY Low; WH- WKY High. 
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Figure 18 Western blot analysis of AMPK protein.  All values are normalized to WKY Con.    
Values represent means ± S.E.M of densiometry analyses.   *p<0.05 vs WKY High.  
Abbreviations: AMPK- AMP activated protein kinase; Con- control; SC- SHR Con; SL-SHR 






















Figure 19: Western blot analysis of phosphorylated AMPK protein at Threonine175.  All 
values are normalized to WKY Con. Values represent means ± S.E.M of densiometry analyses. 
*p<0.01 vs High.  Abbreviations: pAMPK- phosphorylated AMP activated protein kinase; 
Con- control; SC- SHR Con; SL-SHR Low; SH-SHR High; WC-WKY Con; WL-WKY Low; 



















Figure 20: Ratio of phosphorylated AMPK to total AMPK protein. All values are 
normalized to WKY Con ratios.  Values represent means ± S.E.M of densiometry 
analyses. Abbreviations: pAMPK- phosphorylated AMP activated protein kinase; Con- 
control; SC- SHR Con; SL-SHR Low; SH-SHR High; WC-WKY Con; WL-WKY Low; 










Figure 21: Western blot analysis of eNOS protein.  All values are normalized to WKY Con.  
Values represent means ± S.E.M of densiometry analyses. *p<0.01 vs all groups.  
Abbreviations: eNOS- endothelial nitric oxide synthase; Con-control; SC- SHR Con; SL-SHR 
















Figure 22: Western blot analysis of phosphorylated eNOS protein at Serine1177.  All values 
are normalized to WKY Con.  Values represent means ± S.E.M of densiometry analyses. 
*p<0.0001 vs Con and Low.  Abbreviations: peNOS- phosphorylated endothelial nitric oxide 
synthase; Con-control; SC- SHR Con; SL-SHR Low; SH-SHR High; WC-WKY Con; WL-WKY 













Figure 23: Ratio of phosphorylated eNOS to total eNOS protein. All values are 
normalized to WKY Con ratios.  Values represent means ± S.E.M of densiometry 
analyses. *p<0.01 vs WKY Con, #p<0.01 vs SHR Con.  Abbreviations: peNOS- 
phosphorylated endothelial nitric oxide synthase; Con-control; SC- SHR Con; SL-SHR 













Figure 24: Western blot analysis of cytochrome C protein.  All values are normalized to WKY 
Con.  All values are normalized to WKY Con. Values represent means ± S.E.M of densiometry 
analyses.  Abbreviations: Con-control; SC- SHR Con; SL-SHR Low; SH-SHR High; WC-WKY 
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In this study we evaluated the cardioprotective effects of resveratrol treatment on 
hypertensive and normotensive animals by providing a dose of resveratrol in the drinking water 
that mimicked the resveratrol content one could ingest through moderate red wine consumption 
(Low), and a second dose that mimicked the resveratrol amount that one could ingest through 
daily supplemental consumption (High). Secondary to this we investigated protein expression 
in treated and untreated hearts.   
Main Findings: 
1. Chronic resveratrol treatment does not affect animal characteristics, baseline cardiac 
functional parameters, or indices of hypertrophy.   
2. Coronary parameters are not affected by resveratrol treatment at baseline, but are 
affected by strain when normalized to BW or HW.  
3. Chronic resveratrol treatment reduces infarct size, and a High dose protects the 
myocardium against infarction to the same extent as a Low dose.  Strain differences are 
not evident.  
4. Coronary parameters during reperfusion are not affected by resveratrol treatment.   
5. Chronic resveratrol treatment improves functional recovery of contractility (LVDP and 
+dP/dt) to the same extent in WKY and SHR, and a Low dose is as effective as a High 
dose.   
6. Chronic resveratrol treatment at both a High and Low dose protects against contracture 
(LVEDP) during reperfusion to the same extent in WKY and SHR.   





Similarly to the literature (Bradamante et al., 2003; Hung et al., 2004; Rush et al., 
2007), resveratrol treatment did not affect animal characteristics including body weight and 
food consumption, though strain differences were apparent. SHR animals weighed more than 
WKY at the beginning and end of the treatment protocol, and this corresponds with greater 
food and water intake. It is typical for SHR weight gain to diverge from WKY between the 
ages of 13 to 25 weeks (Pfeffer et al., 1979).  Due to increased water intake, SHR High animals 
consumed greater amounts of resveratrol than WKY High, although WKY Low and SHR Low 
groups did not differ.  Although differences existed between the resveratrol intake in SHR and 
WKY in the High groups, this is likely not a limiting factor in our study as the functional data 
does not suggest a dose dependant increase in protection in SHR versus WKY.  As expected 
resveratrol intake was 100 times greater in the High group versus the Low group.   
As planned, when weight-adjusted to the size of a 70Kg human, consumption of 
resveratrol in the Low group (5.5mg/day) mimicked the amount resveratrol attainable through 
daily moderate red wine intake (Faustino et al., 2003), and in the High group (508mg/day) 
mimicked the amount of resveratrol present in supplemental form (Smoliga et al., 2011).    
Strain differences that were expected emerged for indices of hypertrophy.  Hypertrophy 
of the left ventricle is evidenced by 13 weeks of age in SHR (Pfeffer et al., 1979), and was 
evident in our study as demonstrated by increased indices of hypertrophy including HW:BW 
and LVW:BW at 20-22 weeks of age.  Low resveratrol treatment reduced HW across treatment 
groups, as compared to Control, but is simply an artifact of a lesser body weight in this group, 
and not a reduction in hypertrophy.    
Resveratrol treatment did not affect indices of hypertrophy in our study, which 
contrasts with a previous study showing the anti-hypertrophic effects of resveratrol treatment in 
SHR (Thandapilly et al., 2010).  In contrast to our methods, this study used resveratrol 
injections at a much higher concentration than ours, and began treatment at 10 weeks of age, 
for a 10 week period (Thandapilly et al., 2010).  Our treatment differed by lower, 
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physiologically relevant doses, and began later in the developmental phase of hypertension- at 
a time when clinical treatment would be administered to a patient presenting with hypertension.  
It is possible that with a longer treatment period our dosages could produce anti-hypertrophic 
effects. 
Baseline Cardiac Function and Coronary Parameters 
As confirmed by others (Bradamante et al., 2003; Hung et al., 2004; Rush et al., 2007), 
resveratrol treatment at either dose did not affect baseline cardiac function (LVDP, LVEDP, 
+dP/dt). 
Coronary parameters at baseline (CPP, CVR, CDT) were not affected by resveratrol 
treatment in our study; however, strain differences exist.  Recent studies confirm our 
observations that flow per gram in the hypertrophied myocardium of SHR is similar to that of a 
non hypertrophied heart at 22 weeks of age (Susic et al., 2008).  
When normalized to either BW or HW, higher CVR and lower CDT are apparent in 
SHR versus WKY.  Previous studies have confirmed that resistance in coronary arteries is 
increased as a result of hypertensive left ventricular hypertrophy, and that conductance is 
reduced (Kelm et al., 1995; Edoute et al., 1986; Susic et al., 2008).  Acute Resveratrol 
treatment has been shown to elicit a vasodilatory response in isolated porcrine coronary arteries 
(Jäger et al., 1999), and acute incubation of human coronary arteries with red wine extract 
elicits an endothelium dependant dilation (Flesch et al., 1998), though whether these effects 
hold true with chronic resveratrol treatment in the coronary arteries has yet to be determined.  
Using CVR as a measure of vasomotor state, we did not find greater basal vasodilation with 
resveratrol treatment in our study.  The differences are likely attributable to the treatment 
model (acute vs chronic), and artery preparation (isolated from the heart versus intact on an 
isolated heart).  The acute effects are a result of direct stimulation of the endothelium and/or 
smooth muscle with resveratrol incubation.  In contrast to this, any effects of resveratrol on the 
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coronary arteries in our study could only to be due to stored resveratrol within a cell, or 
adaptations to protein expression within a cell.       
Infarct Size  
In a recent study, 27 week old SHR animals with LV hypertrophy demonstrate a greater 
infarct size post ischemia reperfusion than do WKY (~38% vs. ~30% infarcted tissue/total area 
at risk) (Ravingerová et al., 2011).  We found no difference between the infarct size of SHR 
and WKY animals.  Our infarct size in WKY Con is similar to that in the literature, however 
our infarct size in SHR is ~8% less (Ravingerová et al., 2011).  This difference may be due to 
the stage of hypertrophy.  In SHR at and beyond 25 weeks there is dissociation between the 
increase in left ventricular hypertrophy and increasing ventricle diameter such that the 
widening of diameter begins to decline (Pfeffer et al., 1979).   These animals may begin to 
show dysfunction of the myocardium due to altered pumping characteristics, and this may 
affect their tolerance to ischemia.  Our animals were sacrificed around 20 weeks of age, a point 
at which they may not yet show dysfunctional hypertrophy of the myocardium.   
Resveratrol treatment protects against infarction to the same extent in WKY and SHR.  
It appears that there isn’t a dose dependant increase in protection against infarct size.  Other 
research has revealed a dose dependant effect of resveratrol treatment on infarct size in 
Sprague Dawley rats (Hung et al., 2004), though the dosages used in this study were beyond 
the range that our dosages were in (0.5-25mg/Kg/day-i.p.). Our study was designed to use a 
physiologically relevant dose of resveratrol, and to contrast a realistic dietary dose with a 
supplemental dose.  As compared to the literature, our normotensive control and resveratrol 
treated hearts showed ~10% less infarcted tissue (Hung et al., 2000). 
 The reduction in cardiomyocyte death by resveratrol treatment may be a factor of 
reduced oxidative damage, or reduction in apoptotic signaling and an induction of survival 
signaling (Das et al., 2006).  Most importantly, our results demonstrate that the amount of 
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resveratrol present in moderate red wine consumption is as effective as the amount of 
resveratrol in a supplemental dose at providing protection against infarction.  
Ischemia Reperfusion Injury- Functional and Coronary Parameters 
Resveratrol treatment did not affect coronary parameters including CDT, CVR, and 
CPP at 30 minutes, and 2 hours of reperfusion.  Heart rate was not affected at baseline, or 
during reperfusion by resveratrol treatment.  Previous research has demonstrated that chronic 
resveratrol treatment at 2.5, 10, and 25mg/Kg/day-i.p. for 7 days can maintain heart rate near 
baseline values during reperfusion (Mokni et al., 2007), but again most of these concentrations 
are beyond an achievable amount from dietary sources.   
For the first time, our results reveal that both a High and Low dose of resveratrol 
protects against IRI in hypertensive animals.  As resveratrol is a major cardioprotective 
constituent of red wine extract, we expected to find protection against IRI in SHR based on 
previous findings that  chronic treatment with red wine extract protects SHR against IRI 
(Fantinelli et al., 2007). 
 In our study, cardiac functional tolerance to IRI was not lower in SHR animals as 
compared to WKY during reperfusion, which is contradictory to the literature (Golden et al., 
1994; Fantinelli et al., 2007; Snoeckx et al., 1986; Ravingerová et al., 2011). This 
inconsistency may be due to different breeding strains from which the animals were born and 
therefore may have dissimilar genetics.  In SHR, beyond 25 weeks of age, ventricular diameter 
does not increase proportionally to LV hypertrophy, which can cause dysfunctional 
hemodynamics and impaired functional ability (Pfeffer et al., 1979).  This may also explain the 
difference in our study as compared to the literature, as the rats used in other studies were two 
to fourty-two weeks older than ours.  During the progression of hypertension-induced left 
ventricular hypertrophy in Dahl salt sensitive rats a period exists where cardiac response to 
ischemia is improved (Saupe et al., 2000).   If differences in tolerance along the progression of 
hypertrophy in SHR are teased out, we may see similar results to those in Dahl salt sensitive 
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rats, and it may have been during a protective period when our animals were sacrificed.   
Lastly, cardiac myocytes from SHR show increased contractile force in the early stages of 
hypertrophy, and this may act as protective adaptation in our animals (Brooksby et al., 1992).   
Overall, tolerance to IRI was improved in High and Low resveratrol treated hearts, as 
measured by functional parameters including LVDP, LVEDP, and +dP/dt.  Importantly, we did 
not find a significant difference between High and Low treatment on functional recovery.   
Other research has shown dose dependant effects of resveratrol treatment on infarct size in 
Sprague Dawley rats though these dosages were well beyond the range that our dosages were 
in (Mokni et al., 2007).  Most interesting is that a small daily dose of resveratrol that is 
achievable from moderate red wine consumption provides the same cardiac function protection 
as a supplement containing 100 fold the amount of resveratrol.   
Resveratrol treatment did not significantly affect LVDP until the late stages of 
reperfusion. Cell death is a dynamic process and although it may begin during ischemia or at 
the onset of reperfusion, it requires time to complete.  The lack of immediate effect by 
resveratrol treatment on LVDP, but emergence of protection near the end of reperfusion is 
most likely due to reversible injury, or myocardial cells reaching end-point death in Control 
animals, and the sustainment of tissue viability by resveratrol treatment.  Recovery from 
reversible injury is likely a result of repairing oxidative damage and/or resynthesis of 
contractile proteins (Bolli et al., 1999), and in our study, may be an effect of resveratrol’s 
ability to stimulate NO or other antioxidant production, and thereby reduce oxidative stress in 
the myocardium.   
 Resveratrol treatment at both a High and a Low dose significantly improved +dP/dt, 
during reperfusion.  This effect was apparent in both the time-lapse curves, and ∆AUC 
measurements.  Interestingly, when analyzing on a point-by-point basis, High resveratrol 
treatment improved +dP/dt during the entire reperfusion period, whereas Low resveratrol 
treatment did not improve +dP/dt until the late stages of reperfusion.  Since Low resveratrol 
treatment protects against a reduction in LVDP during the entire phase of reperfusion, but does 
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not protect against a reduction in +dP/dt until the late stages of reperfusion, the Low dose must 
either require a greater length of time to reverse damage to contractile apparatus that are 
involved with the time-dependant response of pressure development, or is not high enough to 
protect against cellular changes at the early stages of reperfusion as the High dose does.  
Resveratrol treatment at a High and Low dose significantly maintained LVEDP around 
baseline values during reperfusion, representing a protection by resveratrol against myocardial 
contracture.   Contracture is caused by formation of actin-myosin crossbridges, with the 
inability to deattach (Yellon et al., 2007).  It’s plausible that the reduction in contracture by 
resveratrol is related to either a reduction in Ca
2+ 
overload, or preservation of ATP.  This is 
likely an effect of resveratrol’s ability to upregulate antioxidant enzymes within a cell, thereby 
providing protection to membranes, Ca
2+ 
transporters, and energy producing apparatus in 
response to IRI (Yellon et al., 2007).   
In comparison to the literature, our hearts of both WKY and SHR showed greater 
functional recovery at the relative time points.  LVDP was ~30% higher in our SHR and WKY 
hearts as compared to the literature (Fantinelli et al., 2007), and LVEDP was ~20mmHg lower 
in our hearts as compared to the literature (Fantinelli et al., 2007).  It is difficult to compare the 
outcome of our resveratrol treated hearts to the literature as the bulk of these studies use i.p. 
injection or acute application of resveratrol, and do not take into account digestion.  However; 
our normotensive hearts that were treated with resveratrol show greater functional recovery 
than in the literature, which is likely due to the reduced susceptibility our control animals 
showed as compared to the literature (Ray et al., 1999; Mokni et al., 2007; Dernek et al., 2004).   
Secondary Protein Analysis Findings 
1. Resveratrol treatment at a Low dose effectively reduces COX-1 protein expression in 
both strains.  
2. Resveratrol treatment at a Low dose reduces COX-2 protein expression in WKY.  
COX-2 protein expression was reduced in SHR Control compared to WKY Control.   
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3. Resveratrol treatment at a High dose increases AMPK protein expression in WKY 
animals. Resveratrol treatment at a Low dose significantly increases phosphorylation of 
AMPK as compared to the High dose.  There are no main or interaction effects of the 
phosphorylated AMPK (p-AMPK) to AMPK ratio.   
4. High resveratrol treatment significantly increases eNOS protein expression in SHR 
animals, but does not have an effect on WKY animals.  Activated eNOS is significantly 
increased by High resveratrol treatment.  No strain differences exist.  An interaction 
exists between strain and treatment reflected in the ratio of phosphorylated eNOS (p-
eNOS) to eNOS.   
5. Resveratrol treatment did not affect cytochrome C protein expression in either strain.   
 
From this study we are unable to determine the similarities and differences in mechanisms 
for protection against IRI in SHR and WKY, though our baseline protein analysis will provide 
insight as to which pathways may be contributing to resveratrol induced adaptations, and 
cardioprotection.   
A large body of evidence indicates that myocardial COX-2 can confer protection against 
IRI (Camitta et al., 2001; Yuhki et al., 2011; Bolli et al., 2002).  This is contrary to the negative 
effects of COX derived prostanoids in the vasculature that includes signaling of platelet 
aggregation and resultant cytotoxicity (Yuhki et al., 2010).  This protection exists when COX-2 
is stimulated by NO under ischemia reperfusion conditions (Bolli et al., 2002), and when COX-2 
is constitutively expressed (Inserte et al., 2009).  Additionally COX-1 and COX-2 null mice 
demonstrate reduced tolerance to IRI (Camitta et al., 2001; Yuhki et al., 2011), though the 
protective effects of COX derived protection remains under examination.  Differences between 
COX protein expression in SHR and WKY have yet to be determined, though COX plays a 
role in hypertension, ischemia reperfusion, and LV hypertrophy, suggesting that COX protein 
would be altered in SHR.    
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Our results show a reduction in COX-1 protein in Low treated animals.  This is contrary to 
research demonstrating no effect of resveratrol on COX-1 protein expression in wild type rats, 
undergoing 14 days of 2.5mg/Kg-i.p. resveratrol treatment (Dudley et al., 2008).  Our resveratrol 
treatments are at a slightly lower dose than the literature and are dietary doses, and may 
account for the differences. 
A reduction in COX-2 protein expression in WKY animals treated with a Low resveratrol 
dose was found.  This result was not apparent with High resveratrol treatment, which resulted 
in no change from baseline in WKY animals.  Research applying a resveratrol (2.5mg/Kg-i.p.) 
for two weeks have greatly increased COX-2 protein in Sprague Dawley animals (Dudley et al., 
2008).  Potentially with a higher dose of resveratrol then our High dose a further increase in 
COX-2 protein would have been found in our WKY animals.   This would suggest a ‘J’ or ‘U’ 
shaped curve of COX-2 protein in response to doses of resveratrol as our Low dose reduced 
expression but the High dose did not.  Resveratrol treatment in SHR did not affect COX-2 
protein at either dose.  COX-2 expression in SHR myocardium has not previously been 
reported. We found reduced COX-2 expression in SHR Con as compared to WKY Con.   
AMP- activated protein kinase (AMPK) is an energy sensing protein kinase, and plays a 
protective role in metabolic stress situations such as ischemia.  Resveratrol reduces damage and 
cell death in H9c2 cardiac muscle cells by activating AMPK, when the ROS production of 
ischemic conditions are mimicked using hydrogen peroxide (Hwang et al., 2008).  The effects of 
resveratrol on AMPK during IRI, and the contribution to the overall level of cardioprotection 
has yet to be uncovered, and is an area of interest as activated AMPK is lower in the SHR 
myocardium at 15 weeks (Dolinsky et al., 2009).  AMPK expression in SHR at 20-22 weeks was 
not reduced as compared to WKY in our study.  Interestingly our results show that resveratrol 
treatment affects the expression of AMPK differently in SHR and WKY.  AMPK was only 
increased in WKY High treated hearts.  This suggests that in the diseased, hypertensive state, 
our concentrations of resveratrol are unable to affect protein expression of AMPK.   
62 
 
As mentioned, pAMPK activity is severely reduced in the SHR myocardium at 15 weeks 
(Dolinsky et al., 2009).  Our protein expression analysis for pAMPK revealed no strain 
differences.  Across treatment groups, High resveratrol treatment did not affect pAMPK 
protein as compared to Control, though Low resveratrol treatment slightly increased pAMPK 
content as compared to High treatment. While studies have demonstrated the activation of 
AMPK by resveratrol under stressed conditions, our analysis was completed under resting 
conditions.  Interestingly activation of AMPK by resveratrol inhibits phenylephrine induced 
hypertrophy (Chan et al., 2004), and with further research may prove to be a potential 
mechanism for the inhibition of hypertrophy in the SHR rat as previously observed (Thandapilly 
et al., 2010).   We did not find a large change in activation of AMPK by resveratrol treatment, 
though our measurements were at baseline conditions, and it’s possible that we would see 
greater activation of AMPK in our High treated hearts under stressed conditions as AMPK 
protein expression was increased in these hearts.  The ratio of phosphorylated AMPK to 
AMPK revealed no main or interaction effects.  Despite not reaching significance, the ratio of 
p-AMPK to AMPK in WKY High follows the trends of unchanged p-AMPK, and increased 
AMPK.   
The protective role of eNOS in IRI is well recognized, as are the effects of eNOS 
regulation by resveratrol.   In the left ventricle of 18 week old SHR, there is a ~25% reduction 
in eNOS expression as compared to WKY (Lee et al., 2006; Piech et al., 2003), and this was 
confirmed by our results. Resveratrol treatment at a Low dose did not affect protein levels, but 
at a High dose significantly increased eNOS of SHR, to a level that was nearly double SHR 
Con.  Upregulation of eNOS protein in normotensive animals is seen after 7, and 14, days of 
2.5mg/Kg/day resveratrol treatment (Das et al., 2005; Dudley et al., 2008).  Our research suggests 
resveratrol administered orally increases eNOS expression in hypertensive animals, but is too 
low of a dose to affect eNOS expression in the hearts of normotensive animals.  Due to the 
improvement in functional recovery post IRI being partially NO dependant, and the reduced 
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basal eNOS content in SHR, we would expect upregulation of eNOS by resveratrol in SHR to 
produce protective effects. 
 Phosphorylation of eNOS induces NO production, a key factor in the cardioprotective 
abilities of eNOS, and resveratrol treatment (Das et al., 2006).  Previous research indicates 
increased activation of eNOS by resveratrol treatment in endothelial cells (Wallerath et al., 
2002).  Interestingly, resveratrol treatment did not affect levels of p-eNOS in our study.     Most 
interesting to this area of study is the evidence that although eNOS expression is altered in 
response to hypertension and resveratrol treatment, the myocardium compensates in order to 
maintain the level of p-eNOS, most likely by the alteration of phosphotase and kinase activity. 
This effect is clearly demonstrated by a higher p-eNOS to eNOS ratio, and the reduced eNOS 
expression in SHR Con compared to WKY Con despite no differences in p-eNOS.  
Additionally, this effect is demonstrated by a reduced p-eNOS to eNOS ratio, and a large 
increase in eNOS protein expression SHR High as compared to WKY High, despite yet again 
no differences in p-eNOS.   
 AMPK is an upstream activator of eNOS (Chen et al., 1999).  We found increased AMPK 
content in WKY High hearts, which mimics the increase in p-eNOS protein expression in 
WKY High hearts, but we did not find any significant increases in phosphorylated AMPK 
suggesting that the increased activation of eNOS may be directly through resveratrol, or by 
means of a secondary pathway.  Overall we cannot directly assume that upregulation of eNOS 
activity is producing an increase in NO bioavailability, but this may be an important factor, for 
further study, in the protection afforded by resveratrol against IRI. 
In the current study cytochrome C immunohistochemistry was used to provide a crude 
understanding of resveratrol effects on mitochondrial biogenesis.  Resveratrol can elicit 
mitochondrial biogenesis in endothelial cells (Csiszar et al., 2009) though the effects of 
resveratrol on mitochondrial content in other cells is lacking.  In our study, resveratrol 
treatment did not affect cytochrome C protein expression in the myocardium, and no strain 
differences exist.  Measuring mitochondrial DNA content, or analyzing mitochondrial 
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biogenesis factors would be a more accurate assessment, and may provide better insight into 

























Although we compare our Low resveratrol treatment to the resveratrol content 
attainable through moderate red wine consumption, our results cannot be directly extended to 
studies using red wine or red wine extract as other components of red wine such as ethanol and 
other phenolic compounds, may have confounding effects to those of resveratrol.   
Our calculation of resveratrol consumption requires that all water removed from the 
bottles was consumed by the animal, when infact it is known that a significant level of dripping 
occurs as a result of human or animal movement of the container, or animals playing with the 
spigots.  IP injections are a more accurate way of defining the amount of resveratrol that is 
given to animals, but is a known cause of stress- a factor which can affect the cardiovascular 
function by increasing HR and blood pressure, and affect response to IRI (Ravingerová et al., 
2011).  When treated daily by injection or gavage for 4 weeks, an animals’ cardiovascular state 
may be influenced which is why we chose to apply resveratrol treatment by way of drinking 
water.   
Kidney function in SHR is altered, and may act to impair the clearance of resveratrol as 
compared to the WKY animals.  To assess whether altered kidney function can affect the 
amount of resveratrol that is taken into the blood we would need to assess plasma levels of 
resveratrol in the different strains and treatments.   
Sodium pentobarbital was the anesthetic used in this study, and it is known to depress 
cardiac function while circulating in the bloodstream.  A study using sodium pentobarbital 
anesthesia before heart excision showed a reduction in maximal contractility to increasing Ca
2+
 
in the perfusion medium (Segal et al., 1990).  Other research recommends using barbiturates 
for anesthesia as no complicated equipment is required for administration (Döring, 1990).  We 
chose to use pentobarbital as invasive hemodynamic measurements were taken prior to heart 
excision, and inhalation of volatile agents can stimulate sympathetic nervous system activity, 
and act as a cardioprotective agent (Döring, 1990; Fantinelli et al., 2007).   Ultimately, an ideal 
anesthetic does not exist.  
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The Langendorff isolated heart is void of neural and hormonal control of myocardial 
and coronary function.  Additionally, other circulating factors that are central to ischemia 
reperfusion injury such as platelets do not play a role in this model.  These factors can 
contribute to the myocardium’s response to ischemia reperfusion injury, making our model less 
comprehensive.  In order to include these factors one would need to use a model of in vivo 
coronary artery ligation, which is not a procedure available to our laboratory.   Furthermore, 
interaction between myocytes of ischemic and non ischemic myocardium in a clinical setting 
of thrombotic occlusion is eliminated in our study of global ischemia.  
Our protocol of infarct size staining assumes the infarcted area propagates in a 3-
dimensional manner down through the 1mm slice in the same dimensions as the 2-dimensional 
outline.  This can cause the calculation of infarcted volume of a heart slice to be somewhat 
inaccurate, though the slices are thin and imaging of both sides of the slices allows us to check 
the planimetry for propogation of the infarct through the slice.   
The results of the secondary analysis of protein expression cannot aid in interpretation 
of our functional results as we did not study their activities or change in activation during IR.  
We were; however, able to assess the effects of strain and resveratrol treatment on proteins that 










 This study demonstrates the cardioprotective nature of chronic resveratrol treatment at 
a dose that mimicks the resveratrol content achievable through moderate red wine intake and a 
second dose that mimicks resveratrol supplementation.  Resveratrol treatment protects against a 
depression in cardiac function, and reduces infarct size caused by ischemia reperfusion injury.  
The cardioprotective effects may have been through resveratrol’s ability to act as an anti-
oxidant, anti-inflammatory, or anti-apoptotic signaling agent, though further research is 
required to elucidate the cellular mechanisms by which resveratrol exerts these effects in the 
current hypertensive model.   
 We found that SHR, between 20-22 weeks, with established LV hypertrophy do not 
have increased susceptibility to ischemia reperfusion injury compared to WKY, contrary to the 
literature (Golden et al., 1994; Snoeckx et al., 1989; Ravingerová et al., 2011). Our results may 
reflect a protected stage during the development of LV hypertrophy.   
 We have shown that resveratrol treatment at doses achievable from the diet can induce 
changes to the expression of myocardial proteins that are part of various pathways that play 
cardioprotective roles against IRI.  These protein expression responses to resveratrol differ in 
SHR and WKY, and with future research using isolated hearts and protein antagonists, may 
provide a clearer understanding of mechanisms for resveratrol induced cardioprotection in 
SHR versus WKY.  Future research should attempt to test whether the adaptations to protein 
expression by resveratrol treatment translates into altered activity during IRI, and whether the 
upregulation or downregulation of activity or activation contributes to cardioprotection.   
 As little is known about resveratrol induced-protection against IRI in SHR, the next 
reasonable research direction stemming from this study would be to study specific pathways, 
and their relative contributions to the overall protection.  Research has uncovered the 
dependency on NOS of resveratrol induced cardioprotection in normotensive animals, though 
this pathway does not account for the total protective response (Hung et al., 2004), and may 
play a less significant role in adult hypertensive animals as NOS protein expression is reduced 
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(Piech et al., 2003).  The COX pathway is a novel area for future research as little is 
understood about the effects of resveratrol on COX in the myocardium, let alone a global 
opinion as to the overall effect of COX on IRI.  Additionally, in SHR myocardium of COX is 
understudied as its role in the vasculature has been the forefront of COX research.   
 Future studies should attempt to understand the progression of LV hypertrophy and the 
effects of progression on ischemia reperfusion injury, as previously done in the Dahl salt 
sensitive rats.  Additionally, suggested by the results of our protein analysis showing 
resveratrol affects protein expression differently in SHR and WKY, the mechanisms of 
protection by resveratrol during IRI may prove to be different in SHR and WKY.  Studies 
should attempt to tease out these differences by assessing the contribution of specific pathways 
to the overall response of the heart to IRI, and the influence on these pathways by resveratrol 
during IRI.  This would require Western analysis of protein expression and activation during 
ischemia and reperfusion, in addition to inhibiting certain pathways and analyzing the 
functional outcome in response to IRI.   
 In the future it would be interesting to treat hypertensive animals with our 
physiologically relevant doses of resveratrol before LV hypertrophy begins to develop, in order 
to assess the potential for resveratrol to prevent LV hypertrophy.  This would be similar to the 
study by Thandapilly et al., with the exception of lower, more relevant doses (Thandapilly et 
al., 2010).    
 Lastly, our results provide good evidence of a protective effect of resveratrol treatment 
in SHR, though these methods must be tested on humans to fully understand the possibility of 
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